Source: Eur Respir J, 55 (3) 1901935; 10.1183/13993003.01935-2019
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Lorenzo Guglielmetti, Helena Huerga, Uzma Khan, Francis Varaine. WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion?. Eur Respir J, 55 (3) 1901935; 10.1183/13993003.01935-2019

Member's Comments

No comment yet.

Related content which might interest you: Current approaches to formulate evidence-based recommendations: a case study of WHO drug-resistant tuberculosis treatment guidance Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Source: Eur Respir J 2011; 38: 516-528 Year: 2011 Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion Source: Eur Respir J 2015; 45: 1170-1173 Year: 2015 The impact of national recommendations on antibiotic treatment of community acquired pneumonia. Do pediatricians follow the national guidelines? Source: International Congress 2017 – Pulmonary infection and inflammation Year: 2017 Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement Source: Eur Respir J 2014; 44: 23-63 Year: 2014 The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis Source: Eur Respir J 2016; 48: 963-971 Year: 2016 Is there enough evidence to support recommendations on tuberculosis control? Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis Year: 2008 Getting the best possible evidence from observational studies of treatment of multidrug-resistant tuberculosis patients Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 From international guidelines to local guidelines for nosocomial pneumonia: what is missing? Source: International Congress 2019 – Multidrug resistance in nosocomial pneumonia: burden, magnitude and solution Year: 2019 Epidemiology and clinical management of XDR-TB: a systematic review by TBNET Source: Eur Respir J 2009; 33: 871-881 Year: 2009 The WHO Guidelines for the Programmatic Management of drug-resistant TB: the 2011 update - recommendations and evidence Source: Annual Congress 2011 - ECDC and WHO tuberculosis guidelines: update 2011 (organised within the FP7 funded TB-PAN-NET project) Year: 2011 Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline Source: Eur Respir J , 49 (3) 1700146; DOI: 10.1183/13993003.00146-2017 Year: 2017 A clinical and aetiological evaluation of community acquired pneumonia-are we following guidelines in prescribing antibiotics? Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009 WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidence Source: Eur Respir J, 55 (3) 1902325; 10.1183/13993003.02325-2019 Year: 2020 The new ATS/ERS/IDSA/CDC guidelines for MDR-TB: rationale, methods and recommendations Source: International Congress 2019 – Managing drug-resistant tuberculosis: from new guidelines to clinical practice Year: 2019 Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline Source: Guideline 2020 Year: 2020 Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline Source: Eur Respir J, 56 (1) 2000535; 10.1183/13993003.00535-2020 Year: 2020 Definition of COPD: based on evidence or opinion? Source: Eur Respir J 2008; 31: 681-682 Year: 2008 Are TB services in England adhering to new NICE guidelines on screening for latent TB? Source: International Congress 2017 – Migrants and screening Year: 2017